Literature DB >> 24337140

The preventable burden of productivity loss due to suboptimal asthma control: a population-based study.

Mohsen Sadatsafavi1, Roxanne Rousseau2, Wenjia Chen3, Wei Zhang4, Larry Lynd5, J Mark FitzGerald6.   

Abstract

BACKGROUND: Productivity loss is an overlooked aspect of the burden of chronic health conditions. While modern guidelines emphasize achieving clinical control in asthma management, few studies have reported on the relationship between asthma control and productivity loss. We calculated the productivity loss that can be avoided by achieving and maintaining clinical control in employed adults with asthma.
METHODS: We prospectively recruited a population-based random sample of adults with asthma in British Columbia, Canada. We measured productivity loss due to absenteeism and presenteeism using validated instruments, and ascertained asthma control according to the GINA (Global Initiative for Asthma) classification. We estimated the average gain in productivity for each individual if the individual’s asthma was controlled in the past week, by fitting two-part regression models associating asthma control and productivity loss, controlling for potential confounding variables.
RESULTS: The final sample included 300 employed adults (mean age, 47.9 years [SD 12.0]; 67.3% women). Of these, 49 (16.3%) reported absenteeism, and 137 (45.7%) reported presenteeism. Productivity loss due to presenteeism, but not absenteeism, was associated with asthma control. A person with uncontrolled asthma would avoid $184.80 (Canadian dollars [CAD]) in productivity loss by achieving clinical control during a week, CAD$167.50 (90.6%) of which would be due to presenteeism. The corresponding value was CAD$34.20 for partially controlled asthma and was not statistically significant.
CONCLUSIONS: Our results indicate that substantial gain in productivity can be obtained by achieving asthma control. Presenteeism is more responsive than absenteeism to asthma control, and, thus, is a more important source of preventable burden.

Entities:  

Mesh:

Year:  2014        PMID: 24337140     DOI: 10.1378/chest.13-1619

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network.

Authors:  Gang Wang; Fang Wang; Peter G Gibson; Michael Guo; Wei-Jie Zhang; Peng Gao; Hong-Ping Zhang; Erin S Harvey; Hui Li; Jie Zhang
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Workplace Indirect Cost Impacts of Nasal and Sinus Symptoms and Related Conditions.

Authors:  Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz
Journal:  J Occup Environ Med       Date:  2019-08       Impact factor: 2.162

3.  Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach.

Authors:  Ann-Kathrin Richter; Ludger Klimek; Hans F Merk; Norbert Mülleneisen; Harald Renz; Wolfgang Wehrmann; Thomas Werfel; Eckard Hamelmann; Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Janine Biermann-Stallwitz
Journal:  Eur J Health Econ       Date:  2018-03-24

4.  Disease Control, Not Severity, Drives Job Absenteeism in Young Adults with Asthma - A Nationwide Cohort Study.

Authors:  Kjell Erik Julius Håkansson; Vibeke Backer; Charlotte Suppli Ulrik
Journal:  J Asthma Allergy       Date:  2022-06-20

5.  Comparison of Employer Productivity Metrics to Lost Productivity Estimated by Commonly Used Questionnaires.

Authors:  Bethany T Gardner; Ann Marie Dale; Skye Buckner-Petty; Linda Van Dillen; Benjamin C Amick; Bradley Evanoff
Journal:  J Occup Environ Med       Date:  2016-02       Impact factor: 2.162

6.  Obesity, low levels of physical activity and smoking present opportunities for primary care asthma interventions: an analysis of baseline data from The Asthma Tools Study.

Authors:  Barbara P Yawn; Matthew A Rank; Susan L Bertram; Peter C Wollan
Journal:  NPJ Prim Care Respir Med       Date:  2015-10-01       Impact factor: 2.871

7.  Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.

Authors:  Zafar Zafari; Mohsen Sadatsafavi; Carlo A Marra; Wenjia Chen; J Mark FitzGerald
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 8.  Profile of lebrikizumab and its potential in the treatment of asthma.

Authors:  Diego Jose Maselli; Holly Keyt; Linda Rogers
Journal:  J Asthma Allergy       Date:  2015-08-10

9.  The impact of comorbidities on productivity loss in asthma patients.

Authors:  Solmaz Ehteshami-Afshar; J Mark FitzGerald; Christopher Carlsten; Hamid Tavakoli; Roxanne Rousseau; Wan Cheng Tan; J Douglass Rolf; Mohsen Sadatsafavi
Journal:  Respir Res       Date:  2016-08-26

10.  Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma.

Authors:  Weily Soong; Bradley E Chipps; Sean O'Quinn; Jennifer Trevor; Warner W Carr; Laura Belton; Frank Trudo; Christopher S Ambrose
Journal:  J Asthma Allergy       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.